Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Rectal Cancer
Interventions
DRUG

Bevacizumab

5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)

DRUG

Capecitabine

Starting Dose 650 mg/m\^2 By Mouth Twice Daily Monday-Friday x 6 Weeks

DRUG

Erlotinib

Starting Dose 50 mg By Mouth Daily Weeks 1-3

RADIATION

Radiation Therapy

30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments

PROCEDURE

Surgery

At least 8 weeks after radiation therapy, surgical removal of rectal tumor

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00543842 - Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer | Biotech Hunter | Biotech Hunter